Transforming growth factor-β-stimulated clone-22 is an androgen-regulated gene that enhances apoptosis in prostate cancer following insulin-like growth factor-I receptor inhibition

Clinical Cancer Research

Volumn 15, Issue 24, 2009, Pages 7634-7641

  Sprenger, Cynthia C T ^a,b   Haugk, Kathleen ^c   Sun, Shihua ^a   Coleman, Ilsa ^d   Nelson, Peter S ^a,d   Vessella, Robert L ^b,c   Ludwig, Dale L ^e   Wu, Jennifer D ^a   Plymate, Stephen R ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; COMPLEMENTARY DNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A12; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CASTRATION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 73349122590     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0264     Document Type: Article

References (27)

1. Wu JD, Odman A, Higgins LM, et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgendependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005;11:3065-74.
2. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007; 13:5549-55s.
3. Plymate SR, Haugk K, Coleman I, et al. An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res 2007;13:6429-39.
4. Choi SJ, Moon JH, Ahn YW, Ahn JH, Kim DU, Han TH. Tsc-22 enhances TGF-β signaling by associating with Smad4 and induces erythroid cell differentiation. Mol Cell Biochem 2005;271:23-8.
5. Shostak KO, Dmitrenko VV, Garifulin OM, et al. Downregulation of putative tumor suppressor gene TSC-22 in human brain tumors. J Surg Oncol 2003;82:57-64.
6. Gupta RA, Sarraf P, Brockman JA, et al. Peroxisome proliferator-activated receptor y and transforming growth factor-β pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22. J Biol Chem 2003;278:7431-8.
7. Nakashiro K, Kawamata H, Hino S, et al. Downregulation of TSC-22 (transforming growth factor β-stimulated clone 22) markedly enhances the growth of a human sa l ivary gland cancer cell line in vitro and in vivo. Cancer Res 1998;58:549-55.
8. Nelson P, Clegg N, Arnold H, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A 2002;99:11890-5.
9. Xu Y, Iyengar S, Roberts R, Shappell S, Peehl D. Primary culture model of peroxisome proliferator-activated receptor y activity in prostate cancer cells. J Cell Physiol 2003;196:131-43.
10. Rentsch C, Cecchini M, Schwaninger R, et al. Differential expression of TGF β-stimulated clone 22 in normal prostate and prostate cancer. Int J Cancer 2006;118:899-906.
11. Corey E, Quinn J, Buhler K, et al. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 2003;55: 239-46.
12. Bae V, Jackson-Cook C, Maygarden S, Chen J, Plymate S, Ware J. Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate 1998;34: 275-82.
13. Plymate S, Tennant M, Birnbaum R, Thrasher J, Chatta G, Ware J. The effect of IGF system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. J Clin Endocrinol Metab 1996;81:3709-16.
14. York T, Plymate S, Nelson P, Eaves L, Webb H, Ware J. cDNA microarray analysis identifies genes induced in common by peptide growth factors and androgen in human prostate epithelial cells. Mol Carcinog 2005;44:242-51.
15. Plymate S, Haugk K, Sprenger C, et al. Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by mac25/insulin-like growth factor binding-protein-related protein-1. Oncogene 2003;22:1024-34.
16. Nelson P, Pritchard C, Abbott D, Clegg N. The human (PEDB) and mouse (mPEDB) prostate expression databases. Nucleic Acids Res 2002;30: 218-220.
17. Bonham M, Arnold H, Montgomery B, Nelson PS. Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma. Cancer Res 2002;62:3920-4.
18. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
19. Oh Y, Muller H, Ng L, et al. Transforming growth factor-β-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 1995;270:13589-92.
20. Kawamata H, Fujimori T, Imai Y. TSC-22 (TGF-β stimulated clone-22): a novel molecular target for differentiation-inducing therapy in salivary gland cancer. Curr Cancer Drug Targets 2004;4:521-9.
21. Uchida D, Kawamata H, Omotehara F, et al. Over-expression of TSC-22 (TGF-β stimulated clone-22) markedly enhances 5-fluorouracilinduced apoptosis in a human salivary gland cancer cell line. Lab Invest 2000;80:955-63.
22. True L, Coleman I, Hawley S, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A 2006;103:10991-6.
23. Pandini G, Mineo R, Frasca F, et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 2005;65: 1849-57.
24. Plymate S, Tennant M, Culp S, et al. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors. Prostate 2004;61:276-90.
25. Lu Y, Kitaura J, Oki T, et al. Identification of TSC-22 as a potential tumor suppressor that is upregulated by Flt3-835V but not Flt3-ITD. Leukemia 2007;21:2246-57.
26. Iida M, Anna CH, Gaskin ND, Walker NJ, Devereux TR. The putative tumor suppressor TSC-22 is downregulated early in chemically induced hepatocarcinogenesis and may be a suppressor of Gadd45b. Toxicol Sci 2007;99: 43-50.
27. Hino S, Kawamata H, Uchida D, et al. Nuclear translocation of TSC-22 (TGF-β-stimulated clone-22) concomitant with apoptosis: TSC-22 as a putative transcriptional regulator. Biochem Biophys Res Commun 2000;278: 659-64.